Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8378681 | 0.79 | KMT2A (0.54) | KMT2AMEN1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL22593421 | 0.78 | TSHR (0.38) | KMT2AMEN1ALDH1A1TSHRDPP4 | |
| SCHEMBL18884398 | 0.78 | TSHR (0.36) | KMT2AMEN1ALDH1A1TSHRDPP4 | |
| SCHEMBL29952584 | 0.76 | — | — | |
| SCHEMBL18721344 | 0.74 | — | — | |
| SCHEMBL10260566 | 0.73 | — | — | |
| SCHEMBL30740909 | 0.72 | MCL1 (0.38) | KMT2AMEN1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL28649283 | 0.71 | TSHR (0.42) | KMT2AMEN1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL11177575 | 0.71 | MGAM (0.50) | KMT2AMEN1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL9703018 | 0.71 | KMT2A (0.46) | KMT2AMEN1TSHRHSD17B10MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3151669-B1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | KMT2A 4011/4885MEN1 2850/4885ALDH1A1 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.